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Identity 
Note: 11q23 rearrangements are also -and more often- 
found in de novo leukaemia. 
Clinics and pathology 
Phenotype / cell stem origin 
These treatment related myelodysplasia (t-MDS) or 
leukaemias (t-AL) exhibit variable phenotypes: CMML 
or RAEB±T in MDS cases, ANLL most often (M4 or 
M5a mainly, M1, M2, M5b at times), ALL (and 
biphenotypic leukaemias), often CD19+; t(4;11) cases 
are frequently ALL cases. 
Etiology 
11q23 rearrangements in treatment related leukaemias 
were thought to be found mainly following a treatment 
with anti-topoisomerase II (epipodophyllotoxins) or
with an intercalating topoisomerase II inhibitor 
(anthracyclins), as for some 21q22 rearrangements; 
actually, they may also be found after alkylating agents 
treatment and/or radiotherapy; the prior cancer is 
variable: breast cancer, non-Hodgkin lymphoma, 
Hodgkin disease, leukaemia, lung carcinoma, and other 
malignancies. 
Epidemiology 
Up to 30% of t(11;19)(q23;p13.1), 10% or more of 
t(9;11), 5% of t(4;11) and 5% of t(10;11) are found i  
secondary leukaemias: altogether 5 to 10% of 11q23 
leukaemias are treatment related; these 11q23 second 
leukaemias are found at any age, from infancy to elder 
age. 
Clinics 
Latency for the outcome of the second leukaemia after  
 
 
the first cancer is often short (med 2 yrs), but highly  
variable, and may not depend on the type of treatment 
received; it is however most often shorter than in cases 
of second leukaemias associated with -5/del(5q) or with 
-7/del(7q). 
Prognosis 
Is poor, as in other therapy related leukaemias; in a 
recent excellent study (n=40), only 80% of patients 
achieved remission, 3/4 relapsed within a year; median 
remission duration being 5 mths. 
Cytogenetics 
Cytogenetics, morphological 












del(6q), -7/del(7q), del(17p). 
Genes involved and Proteins 
MLL 
Location: 11q23 
DNA / RNA 
21 exons, spanning over 100 kb; 13-15 kb mRNA. 
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Protein 
431 kDa; contains two DNA binding motifs (a AT 
hook, and Zinc fingers), a DNA methyl transferase 
motif, a bromodomain; transcriptional regulatory 
factor; nuclear localisation. 
Variable gene, from a variable 
chromosome partner: 
AF1p (1p32), AF1q (1q21), AF4 (4q21), AF6 (6q27), 
AF9 (9p22), AF10 (10p12), CBP (16p13), ENL 
(19p13.3), ELL (19p13.1). 
DNA / RNA 
These genes appear to have, in most cases, no apparent 
homology to each other; for DNA and protein 
description of each, refer to their gene entry. 




5' MLL - 3' partner. 
Fusion protein 
Description 
N-term AT hook and DNA methyltransferase from 
MLL fused to (little or most of) the partner C-term part. 
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